Acamprosate: Pharmacoeconomic implications of therapy

PharmacoEconomics

Volumn 16, Issue 6, 1999, Pages 743-755

  Foster, Rachel H ^a   McClellan, Karen J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE;

ALCOHOLISM; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DETOXIFICATION; GASTROINTESTINAL TOXICITY; HUMAN; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

EID: 0033458029     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199916060-00010     Document Type: Review

References (47)

1. DSM-IV. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
2. Schuckit MA. Alcohol and alcoholism. In: Isselbacher KJ, Martin JB, Braunwald E, et al., editors. Harrison's principles of internal medicine. 13th ed. New York: McGraw-Hill, 1994: 2420-5
3. Wilde MI, Wagstaff AJ. Acamprosate: a review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 1997 Jun; 53: 1038-53
4. Kessler RC, Crum RM, Warner LA, et al. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 1997 Apr; 54: 313-21
5. Helzer JE, Burnam A, McEvoy LT. Alcohol abuse and dependence. In: Robins LN, Regier DA, editors. Psychiatric disorders in America: the Epidemiologic Catchment Area Study. New York: Free Press 1991: 81-115
6. Mirand AL, Welte JW. Alcohol consumption among the elderly in a general population, Erie County, New York. Am J Public Health 1996 Jul; 86: 978-84
7. Fink A, Hays RD, Moore AA, et al. Alcohol-related problems in older persons: determinants, consequences, and screening. Arch Intern Med 1996 Jun 10; 156: 1150-6
8. Glynn RJ, Bouchard GR, LoCastro JS, et al. Aging and generational effects on drinking behaviors in men: results from the normative aging study. Am J Public Health 1985 Dec; 75: 1413-9
9. Schultz JM. Alcohol-related mortality and years of potential life lost - United States 1987. MMWR Morb Mortal Wkly Rep 1990; 39 (11): 173-8
10. American Psychiatric Society. Practice guideline for the treatment of patients with substance use disorders: alcohol, cocaine, opioids. Am J Psychiatry 1995 Nov; 152 (11 Suppl.): 1-59
11. Wu L-T, Kouzis AC, Leaf PJ. Influence of comorbid alcohol and psychiatric disorders on utilization of mental health services in the National Comorbidity Survey. Am J Psychiatry 1999 Aug; 156 (8): 1230-0
12. Gearhart JG, Beebe DK, Milhorn HT, et al. Alcoholism in women. Am Fam Physician 1991 Sep: 44: 907-13
13. Welsh JA, Buchsbaum DG, Kaplan CB. Quality of life of alcoholics and non-alcoholics: does excessive drinking make a difference in the urban setting? Qual Life Res 1993 Oct; 2: 335-40
14. Foster JH, Powell JE, Marshall EJ, et al. Quality of life in alcohol-dependent subjects: a review. Qual Life Res 1999; 8: 255-61
15. Rice DP. The economic cost of alcohol abuse and alcohol dependence: 1990. Alcohol Health Res World 1993; 17 (1): 10-1
16. Wilde MI, Goa KL. Management of alcohol dependence after detoxification: the potential role of acamprosate. Dis Manage Health Outcomes 1998 Jan; 3: 35-46
17. Roberts KS, Brent EE. Physician utilization and illness patterns in families of alcoholics. J Stud Alcohol 1982; 43 (1): 119-28
18. Burke TR. The economic impact of alcohol abuse and alcoholism. Public Health Rep 1988 Nov-Dec; 103: 564-8
19. Langsdale T. A sobering look at the cost of alcoholism. Pharmacoresources 1995 Jul 8; 32: 3-4
20. Portella E, Ridao M, Carrillo E, et al. El alcohol y su abuso: impacto socioeconómico. Madrid: Editorial Médica Panamericana, S.A., 1998
21. Brecht JG, Poldrugo F, Schädlich PK. Alcoholism: the cost of illness in the Federal Republic of Germany. Pharmacoeconomics 1996 Nov; 10: 484-93
22. Langenbucher J. Rx for health care costs: resolving addictions in the general medical setting. Alcohol Clin Exp Res 1994 Sep-Oct; 18: 1033-6
23. Holder HD, Blose JO. Alcoholism treatment and total health care utilization and costs: a four-year longitudinal analysis of federal employees. JAMA 1986 Sep 19; 256: 1456-60
24. Holder HD, Blosc JO. The reduction of health care costs associated with alcoholism treatment: a 14-year longitudinal study. J Stud Alcohol 1992; 53 (4): 293-302
25. Littleton J. Acamprosate in alcohol dependence: how does it work? Addiction 1995 Sep; 90: 1179-88
26. Spanagel R, Zieglgänsberger W. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci 1997 Feb; 18: 54-9
27. ABPI compendium of data sheets and summaries of product characteristics 1998-1999. London: Datapharm Publications Ltd, 1998
28. Soyka M. Relapse prevention in alcoholism: recent advances and future possibilities. CNS Drugs 1997 Apr: 7: 313-27
29. Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999 Apr 14; 281: 1318-25
30. Sass H, Soyka M, Mann K, et al. Relapse prevention by acamprosate: results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996 Aug; 53: 673-80
31. Whitworth AB, Fischer F, Lesch OM, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996 May 25; 347: 1438-42
32. Paille FM, Guelfi JD, Perkins AC, et al. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 1995 Mar; 30: 239-47
33. Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 1997 Nov; 92: 1537-46
34. Pele I, Verbanck P, Le Bon O, et al. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients: a 90-day placebo-controlled dose-finding study. Br J Psychiatry 1997 Jul; 171: 73-7
35. DSM-III-R. Diagnostic and statistical manual of mental disorders. 3rd revised ed. Washington, DC: American Psychiatric Association, 1987
36. Feuerlein W, Ringer C, Küfner H, et al. Diagnosis of alcoholism: the Munich Alcoholism Test (MALT). In: Galanter M, editor. Currents of alcoholism. v. 7. New York (NY): Grune & Stratton, 1980: 137-47
37. DSM-III. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980
38. Besson J, Aeby F, Kasas A, et al. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 1998 May; 22: 573-9
39. Sass H, Polgieter AS, Lehert P. Acamprosate and relapse prevention: results from a pooled analysis of 11 randomised placebo-controlled trials in 3338 alcohol-dependent patients [abstract]. Eur Neuropsychopharmacol 1996 Sep; 6 Suppl. 4: 7
40. Schädlich PK, Brecht JG. The cost effectiveness of acamprosate in the treatment of alcoholism in Germany: economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study. Pharmacoeconomics 1998 Jun; 13: 719-30
41. Todd C. 'Cheers' to acamprosate in reducing the costs of alcoholism. Pharmacoecon Outcomes News 1999 Feb 27; 201: 3-4
42. Annemans L, Vanoverbeke N. Economic evaluation of acamprosate in maintaining abstinence in alcohol-dependent patients [abstract]. Value Health 1999 Jan/Feb; 2 (1): 8
43. Milne RJ. Pharmacoeconomic models in disease management: a guide for the novice or the perplexed. Dis Manage Health Outcomes 1998 Sep: 4 (3): 119-34
44. McCrady BS, Langenbucher JW. Alcohol treatment and health care system reform. Arch Gen Psychiatry 1996 Aug; 53: 737-46
45. Schaffer A, Naranjo CA. Recommended drug treatment strategies for the alcoholic patient. Drugs 1998 Oct; 56: 571-85
46. Swift RM. Drug therapy for alcohol dependence. N Engl J Med 1999 May 13; 340: 1482-90
47. Hoes M. Relapse prevention in alcoholics: a review of acamprosate versus naltrexone. Clin Drug Invest 1999 Mar; 17: 211-6